BTCC
/
BTCC Square
/
Global Cryptocurrency
/
Sanofi Stock Drops 9% as Eczema Drug Trial Results Disappoint
Sanofi Stock Drops 9% as Eczema Drug Trial Results Disappoint
23
1
BTCCSquare news:
Sanofi shares tumbled 9% after late-stage trial data for its experimental eczema treatment amlitelimab failed to meet elevated investor expectations. While the drug achieved its primary endpoints, analysts noted its performance lagged behind competing biologics.
The French pharma giant emphasized amlitelimab's potential as a quarterly-administered therapy that could eventually succeed its blockbuster Dupixent, which faces patent expiration in 2031. Sanofi projects peak sales exceeding $5 billion for the new treatment.
By:
